Irish pharma company signs new distribution agreement
Irish-listed Amryt Pharma, which is focused on finding treatments for rare and orphan diseases, has signed a distribution agreement for the company’s Lojuxta (lomitapide) product covering Romania and Bulgaria.
The agreement has been signed with Romastru Trading, a Bucharest-based pharmaceutical services company that is part of Pharaon Healthcare Europe.
Pharaon Healthcare is a conglomerate that provides a wide range of services, including medical, marketing research, storage and distribution.
"We are pleased to have signed this agreement with Romastru, a long-established pharmaceutical services company based in Bucharest," Dr. Joe Wiley, chief executive of Amryt Pharma, said.
"Romastru's reach across Romania and Bulgaria means that we can now provide comprehensive access to Lojuxta for adult patients suffering from HoFH in these territories."
Lojuxta is a treatment for Homozygous Familial Hypercholesterolaemia ("HoFH"), a rare, life-limiting disease, which impairs the body's ability to remove bad cholesterol from the blood.
The disease process starts before birth and progresses rapidly, and typically results in extremely high bad cholesterol levels in blood, leading to aggressive and premature narrowing and blocking of blood vessels.
The agreement is the fourth such agreement signed by Amryt in the last three months, and it broadens further the company's distribution footprint for Lojuxta in central and eastern Europe.
The company aims to complete further agreements across its in-licenced territories in Europe, Middle East and Africa as the year progresses.